Advances in the use of PARP inhibitor therapy for breast cancer
Poly-ADP-ribose polymerase 1 (PARP-1) and PARP-2 are DNA damage sensors that are most active during S-phase of the cell cycle and that have wider-reaching roles in DNA repair than originally described. BRCA1 and BRCA2 (Breast Cancer) proteins are involved in homologous recombination repair (HRR), wh...
Main Authors: | Kelly E McCann, Sara A Hurvitz |
---|---|
Format: | Article |
Language: | English |
Published: |
BioExcel Publishing Ltd
2018-08-01
|
Series: | Drugs in Context |
Subjects: | |
Online Access: | https://www.drugsincontext.com/advances-in-the-use-of-parp-inhibitor-therapy-for-breast-cancer |
Similar Items
-
Current status and future prospects of PARP inhibitor clinical trials in ovarian cancer
by: Jiang X, et al.
Published: (2019-05-01) -
Hematological Toxicities with PARP Inhibitors in Prostate Cancer: A Systematic Review and Meta-Analysis of Phase II/III Randomized Controlled Trials
by: Gartrell C. Bowling, et al.
Published: (2023-10-01) -
Therapeutic Potential of PARP Inhibitors in the Treatment of Metastatic Castration-Resistant Prostate Cancer
by: Albert Jang, et al.
Published: (2020-11-01) -
Use of First-Line PARP Inhibitors in Ovarian Cancer
by: Ursula Hasler-Strub
Published: (2020-11-01) -
Liposome Formulations for the Strategic Delivery of PARP1 Inhibitors: Development and Optimization
by: Carlota J. F. Conceição, et al.
Published: (2023-05-01)